Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05626491 · ClinicalTrials.gov registry record · NA
Electrical Stimulation for the Treatment of Glaucoma
A NA study of Glaucoma and Glaucoma Open-Angle, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 4
- Study locations
NCT05626491: Recruiting NA study of Glaucoma and Glaucoma Open-Angle, sponsored by Stanford University.
NCT05626491 is a NA study of Glaucoma and Glaucoma Open-Angle that is actively recruiting participants, run by Stanford University. The registered enrollment target is 45 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05626491, a NA study of Glaucoma and Glaucoma Open-Angle, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 4
- Study locations
Study Summary
The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.
Conditions Studied
Interventions
- DEVICE Repetitive, Transorbital Alternating Current Stimulation (rtACS)
- DEVICE Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Study Locations (4)
California
- Byers Eye Institute - Palo Alto
New York
- NYU- Langone - New York
Pennsylvania
- Wills Eye Hospital - Philadelphia
Other
- Otto-von-Guericke University - Magdeburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-02-28 |
| Est. Completion | 2025-12 |
| Phase | NA |
What NCT05626491 shows while recruiting
NCT05626491 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Repetitive, Transorbital Alternating Current Stimulation (rtACS) is the first listed.
NCT05626491 reports a single indexed study location in California, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05626491 about?
NCT05626491 is a clinical study titled "Electrical Stimulation for the Treatment of Glaucoma". The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your e...
What is the current status of trial NCT05626491?
This trial is currently recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2023-02-28. Estimated completion is 2025-12.
What conditions does trial NCT05626491 study?
This clinical trial studies the following conditions: Glaucoma, Glaucoma Open-Angle.
What interventions are being tested in trial NCT05626491?
The interventions under investigation include: Repetitive, Transorbital Alternating Current Stimulation (rtACS) (DEVICE), Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS) (DEVICE).
Who is sponsoring clinical trial NCT05626491?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05626491 being conducted?
This trial has 4 study locations across California, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05626491's enrollment target sits among peer trials
45 70th of 92 higher than 22 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Tolerability of an Anesthesia-free Tonometer Tip
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Optic Neuropathies
RECRUITING · NA
-
The Role of Music in Enhancing Attention During Visual Field Exams for Pediatric Glaucoma Patients
RECRUITING · NA
-
Hyperbaric Oxygen Therapy for Optic Neuropathies
RECRUITING · NA
-
Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI